Günlük veya Haftalık Alendronat veya Risendronat Alan Postmenopozal Osteoporozlu Kadınlarda Aylık İbandronat İçin Hasta Tercihinin Değerlendirildiği Açık-Etiketli, Prospektif, Çok-Merkezi, İki-Aşamalı Çalışma-BONCURE: Türkiye Alt-Çalışması

Aim: BONCURE (Bonviva for Current Bisphosphonate Users Regional European Trial), aimed to evaluate patient preference with monthly\udibandronate in women with postmenopausal osteoporosis who previously received daily or weekly alendronate or risendronate.\udMaterials and Methods: This prospective, open-label study consisted of two sequential stages, Part A (screening) and Part B (treatment). Patients enrolled\udinto Part A completed the Candidate Identification Questionnaire (CIQ). In Part B, after completing the Osteoporosis Patient Satisfaction Questionnaire (OPSATQ),\udpatients received monthly oral ibandronate 150 mg for 6 months. Following treatment, patients completed the OPSAT-Q and Preference Questionnaire.\udResults: A total of 223 patients (mean age, 63.7±9.51 years) were enrolled in Part A from Turkey. Among them, 103 (46.2%) answered “YES” to at least\udone CIQ question. The mean composite OPSAT-Q domain scores increased for convenience (mean change, 15.3±17.7 points), quality of life (10.4±20.4\udpoints), overall satisfaction (11.9±22.7 points), and side effects (3.3±18.8 points). At month 6, 177 subjects (92.7%) preferred once-monthly dosing schedule\udand 99.0% were compliant (≥80%) with study treatment. Thirty (15.6%) subjects experienced mild to moderate adverse events, mostly gastrointestinal.\udConclusion: Postmenopausal women with osteoporosis prefer and are more satisfied and compliant with monthly dosing of ibandronate than\uddaily or weekly bisphosphonate treatment. (Turkish Journal of Osteoporosis 2012;18:1-7